摘要
目的:探讨胰腺癌中脆性三联组氨酸(Fragilehistidinetriad,FHIT)基因蛋白Fhit表达状况及其与临床病理指标的可能关系。方法:采用兔抗人Fhit蛋白抗体和枸橼酸-微波-SP免疫组化方法检测50例福尔马林固定、石蜡包埋的胰腺癌蜡块标本中Fhit表达状况并分析其与组织学分类、组织学分级以及淋巴结转移的关系。结果:癌组织Fhit表达阳性率为78%(39/50);而正常胰腺组织Fhit表达阳性率为94%(47/50),二者比较,差异有显著性(P=0.020)。癌组织Fhit表达强度较正常胰腺组织高者为10例(20.0%);较正常胰腺组织低者为28例(56.0%),其中11例为阴性(22.0%);与正常胰腺相等者为12例(24.0%)。Fhit蛋白低表达癌组织中Fhit染色阳性细胞数量及强度较其正常胰腺组织明显减少及降低。管状腺癌组Fhit蛋白表达降低阳性率与非管状腺癌组(3/5)比较,差异无显著性(P=1.000)。50例胰腺癌中,Ⅰ级癌Fhit蛋白表达降低阳性率为12.5%(1/8),Ⅱ级癌为65.0%(13/20),Ⅲ级癌63.6%(14/22),Ⅰ级癌与Ⅱ~Ⅲ级癌组比较,差异有显著性(P=0.015)。伴局部淋巴结转移的胰腺癌Fhit蛋白表达降低阳性率为84.6%(11/13),无淋巴结转移癌为45.9%(17/37),已伴淋巴结转移癌组与未转移癌组比较,差异有显著性(P=0.023)。结论:胰腺癌Fhit表达状况可能与组织学分类、分级以及?
Objective:The aim of t his stud y is to investigate the expression of fragile histidine triad gene protein,Fhit and the possible relationship between Fhit expression and clinicopathological i ndices in pancreatic carcinoma.Methods:Detecting Fhit protein expression in5 0cases of formalin-fixed,paraffin-embedded colorectal carcinoma and analysi ng its relationship to histological classification,grade,and lymphatic metasta sis were performed by rabbit antibody to human FHIT gene protein with citrate-m icrowave-SP immunohistochemical method.Results:Fhit expression was detected p ositive in thirty-nine(78%)cases of carcinoma,and in forty-seven(94% )of normal pancreatic tissue,respectively.There was a significant difference in Fhit expression between the cancer tissue and the normal tissue(P=0.02 0).56.0%of carcinomas showed a marked loss or absence of Fhit expression compared with their matched normal tissue.The carcinoma with reduced expressi on of Fhit was corresponding to histological grade(P=0.015),and lym pha tic metastasis(P=0.023)but not to histological classification(P=1. 000).Conclusions:The re duced expression of Fhit may be associated with de creasing differentia tion and metastasis in the pancreatic carcinoma.It is sugg ested that the decreased Fhit expression plays an importan t role in the development and progression of the tumor,and thus may become a new prognostic marker in pancreatic carcinoma.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2003年第1期20-22,33,共4页
Chinese Journal of Clinical Oncology